Clinical, pathologic, and genetic features of the clinical subgroups of acute erythroid leukemia
| Feature . | N-AEL, n = 44 . | MDS-AEL, n = 40 . | T-AEL, n = 40 . | Statistical comparison . |
|---|---|---|---|---|
| Median age, y | 60 | 67 | 65 | P = .003 MDS-AEL vs N-AEL |
| Median hemoglobin, g/L | 87 | 95 | 91 | P = .008 MDS-AEL vs N-AEL |
| Median platelet count, ×109/L | 47 | 49 | 43 | NS |
| Median absolute neutrophil count, ×109/L | 0.76 | 0.90 | 0.70 | NS |
| Mean peripheral blood blasts, % | 6.8 | 4.1 | 5.7 | NS |
| Median red cell mean corpuscular volume, fL | 91.4 | 92.9 | 91.0 | NS |
| Mean reticulocyte count | 0.023 | 0.026 | 0.030 | NS |
| Mean peripheral blood nucleated red cells/100 white blood cells | 24 | 13 | 15 | NS |
| Median marrow cellularity, % | 90 | 80 | 70 | P = .02 N-AEL vs T-AEL; P = .05 N-AEL vs MDS-AEL |
| Median marrow erythroid percentage | 61.5 | 61 | 64 | NS |
| Median marrow blast percentage of all cells | 13 | 11.5 | 10 | NS |
| Median marrow blast percentage of nonerythroid cells | 34 | 30 | 32 | P = .003 N-AEL vs MDS-AEL |
| Mean no. of dysplastic hematopoietic lineages | 2.18 | 2.26 | 2.11 | NS |
| Ring sideroblasts, no. of cases with finding | 9/38 | 7/38 | 7/34 | NS |
| United Kingdom Medical Research Council cytogenetic risk grouping, favorable/intermediate/unfavorable | 0/24/20 | 0/22/17 | 0/4/32 | P = .001 N-AEL vs T-AEL; P < .001 MDS-AEL vs T-AEL |
| International Prognostic Scoring System cytogenetic risk grouping, good/intermediate/poor | 12/10/22 | 17/5/17 | 2/1/33 | P = .001 N-AEL vs T-AEL; P < .001 MDS-AEL vs T-AEL |
| Feature . | N-AEL, n = 44 . | MDS-AEL, n = 40 . | T-AEL, n = 40 . | Statistical comparison . |
|---|---|---|---|---|
| Median age, y | 60 | 67 | 65 | P = .003 MDS-AEL vs N-AEL |
| Median hemoglobin, g/L | 87 | 95 | 91 | P = .008 MDS-AEL vs N-AEL |
| Median platelet count, ×109/L | 47 | 49 | 43 | NS |
| Median absolute neutrophil count, ×109/L | 0.76 | 0.90 | 0.70 | NS |
| Mean peripheral blood blasts, % | 6.8 | 4.1 | 5.7 | NS |
| Median red cell mean corpuscular volume, fL | 91.4 | 92.9 | 91.0 | NS |
| Mean reticulocyte count | 0.023 | 0.026 | 0.030 | NS |
| Mean peripheral blood nucleated red cells/100 white blood cells | 24 | 13 | 15 | NS |
| Median marrow cellularity, % | 90 | 80 | 70 | P = .02 N-AEL vs T-AEL; P = .05 N-AEL vs MDS-AEL |
| Median marrow erythroid percentage | 61.5 | 61 | 64 | NS |
| Median marrow blast percentage of all cells | 13 | 11.5 | 10 | NS |
| Median marrow blast percentage of nonerythroid cells | 34 | 30 | 32 | P = .003 N-AEL vs MDS-AEL |
| Mean no. of dysplastic hematopoietic lineages | 2.18 | 2.26 | 2.11 | NS |
| Ring sideroblasts, no. of cases with finding | 9/38 | 7/38 | 7/34 | NS |
| United Kingdom Medical Research Council cytogenetic risk grouping, favorable/intermediate/unfavorable | 0/24/20 | 0/22/17 | 0/4/32 | P = .001 N-AEL vs T-AEL; P < .001 MDS-AEL vs T-AEL |
| International Prognostic Scoring System cytogenetic risk grouping, good/intermediate/poor | 12/10/22 | 17/5/17 | 2/1/33 | P = .001 N-AEL vs T-AEL; P < .001 MDS-AEL vs T-AEL |
N-AEL indicates de novo acute erythroid leukemia; MDS-AEL, acute erythroid leukemia after antecedent hematologic neoplasm or chronic cytopenia; T-AEL, therapy-related acute erythroid leukemia; and NS, not significant.